University of California

The University of Arizona

Northwestern University

Other

Cognis Australia Pty., Ltd.

Cancer Prevention Pharmaceuticals, Inc.

Frank L Meyskens

Eugene W Gerner

Jason A Zell

Christine E McLaren

Hoda Anton-Culver

Richard B Silverman

Haitao Ji

Fengtian Xue

Sun Yang

Patricia Thompson

Thomas L Poulos

Ryan Dellinger

Particia A Thompson

Julie A Buckmeier

Lance Elliot Schlipalius

Ryan W Dellinger

Eugene Gerner

Jason Zell

Kavitha P Raj

Christine Mclaren

Patricia A Thompson

Jeffrey Jacob

A chemoprotective method for treating, inhibiting or preventing loss of barrier function in skin caused by ultraviolet (UV) light by using an effective amount of pterostilbene is provided. Pharmaceutical and nutraceutical compositions containing pterostilbene suitable for administration to an individual in order to prevent subsequent UV-mediated loss of barrier function in skin are provided.

Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin

The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.

Carcinoma diagnosis and treatment, based on ODC1 genotype

[object Object]

Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Specific nNOS inhibitors for the therapy and prevention of human melanoma

Inhibitors of nitric oxide synthase for treatment of melanoma

A method of inhibiting carcinogen mediated conversion of melanocyte cells and protecting DNA against carcinogen-mediated damage by administering a composition comprising a water insoluble carotenoid such as beta-carotene is disclosed.

Carotenoid agent for inhibiting the conversion of epithelial cells to tumors

Activation of the Ki-ras proto-oncogene is common in colon carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit carcinogen-induced colon carcinogenesis, decrease the frequency of Ki-ras mutations in the azoxymethane-treated rat model, and induce apoptosis in a variety of cell types. Sulindac, as well as other non-steroidal anti-inflammatory agents, are provided in combination with DFMO the prevention and/or treatment of cancers characterized by the expression of an activated Ki-ras. Provided with the present invention are pharmaceutically acceptable compositions that include a non-steroidal anti-inflammatory agent, sulindac, together with an effective amount of difluoromethylornithine.

DFMO and sulindac combination in cancer chemoprevention

Growing community of inventors

Irvine, CA, United States of America

Frank L Meyskens